<DOC>
	<DOCNO>NCT01640457</DOCNO>
	<brief_summary>NOVOCART® Disc plus investigate explore clinical applicability , safety efficacy repair herniated disc indication elective sequestrectomy , adjacent degenerate disc , present . The objective clinical study provide basis confirmatory study design ( endpoint , methodology ) ( Phase II ) , develop safety profile ( Phase I ) . This study aim develop validate know new biologic marker quality clinical efficacy product request context identity , purity potency characteristic medicinal/investigational product .</brief_summary>
	<brief_title>Safety Efficacy With NOVOCART® Disc Plus ( ADCT ) Treatment Degenerative Disc Disease Lumbar Spine</brief_title>
	<detailed_description>This classical Phase II study implicate Phase I part . The Phase I/II combination study non-confirmatory study aim gather preliminary clinical information NOVOCART® Disc plus use new indication repair herniated disc . It conduct prospective , multicenter , unmasked , clinical trial include 120 subject randomize NOVOCART® Disc plus ( NDplus , 60 subject ) , medium NOVOCART® Disc basic active cell component ( NDbasic , 36 subject ) standard care ( SC ) sequestrectomy control ( 24 subject ) . 24 patient enrolled Phase I study ( 12 NDplus , 12 NDbasic ) 96 patient Phase II ( 48 NDplus , 24 NDbasic , 24 SC ) . All subject evaluate 1.5- , 3- , 6- , 12- , 24- , 36- , 48-months post-t0 examination SC study arm 1.5- , 3- , 6- , 12- , 24- , 36- , 48-months post-t5 examination NDplus NDbasic study arm , 5 year post-t0/t5 collect long-term clinical data . Efficacy measurement functional improvement evaluate among NDplus , NDbasic SC . Physiological effect observe MRI measurement compare appropriate treatment depend expect treatment mechanism . Safety data NDplus combine NDbasic contrast SC procedure relate risk NDplus NDbasic SC together graft-related adverse experience . To optimize usefulness clinical information , data collect study may analyze review continuously . Early finding may use modify study design deem appropriate acceptable Sponsor 's medical advisor . Data-driven adaptive action include limited stop enrollment early . The Sponsor inform regulatory body , Ethic Committees , investigator implement study design modification . Cells tissue collect study use vitro-controlled experiment aim develop validate know novel biologic marker quantify cell quality context identity , purity potency . Prognostic value biologic marker examine correlate clinical data collect study . The study follow subject total five year post-t0 examination SC study arm post-t5 examination NDplus NDbasic study arm obtain long-term performance data . Patients must single-level acute disc herniation indication elective sequestrectomy . They may correspond disc degeneration proximal adjacent segment ( Pfirrmann Score Stage 3-4 ) . A total 120 adult enrol study . Each patient remain study 5 year post t0/t5 examination complete plan follow-up phase . It expect take 6 year five month collect require data study .</detailed_description>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<criteria>1 . The patient disc herniation back and/or leg pain ( radicular pain ) 2 . The patient indication sequestrectomy accord guideline DGNC DGOOC 3 . The patient 1860 year age . 4 . The patient physically mentally able participate study , able understand study , goal possible risk factor involve . The patient willing able participate followup visit plan study site able understand complete studyrelevant questionnaire German language . 5 . The patient sufficiently inform trial orally write . S/he enough time consideration , willing participate study give her/his write informed consent . 6 . The patient confirm s/he participate clinical study 90 day prior study inclusion . S/he agree refrain participate another clinical study NOVOCART® Disc Study another 90 day study termination Radiological Inclusion Criteria Patients must meet follow criterion consider enrollment NOVOCART® Disc study . 1 . The patient singlelevel lumbar disc herniation 2 . The patient 50 % remain disc height herniated disc comparison unaffected discs lumbar spine . If discs show degenerative sign , disc height least 5 mm 3 . The patient obvious sign osteophytes end plate sclerosis lumbar segment treat NOVOCART® Disc plus oder NOVOCART® Disc basic Patients without adjacent degenerative disc ( HD ) : 4 . The adjacent proximal disc degenerative sign accord Pfirrmann Score stage 3 5 . Patients adjacent degenerative disc ( AAD ) : 4 . The patient additional degenerative sign proximal adjacent lumbar level accord Pfirrmann 34 , 25 % disc height reduction 1 . The patient previous surgery lumbar level ( ) treat NOVOCART® Disc plus oder NOVOCART® Disc basic . 2 . The patient past recurrent disc herniation treat sequestrectomy relevant disc . 3 . The patient degenerative muscular neurological condition would interfere evaluation outcome measure include limit Parkinson 's disease , amyotrophic lateral sclerosis , multiple sclerosis , muscular dystrophy myelopathic disease different cause . 4 . BMI &gt; 35 kg/m2 5 . The patient current recent history illicit drug , nicotine ( 20 cigarette per day ) alcohol abuse dependence 6 . CRP &gt; 10mg/dl 7 . The patient pregnant , breastfeed actual planning become pregnant . Female patient must either least two year postmenopausal use one follow mean birth control treatment phase , i.e . transplantation surgical sterility double barrier method , e.g . condom diaphragm combination spermicide intrauterine contraceptive device bilateral vasectomy sexual partner least 90 day prior enrolment combination barrier method ( e.g . condom diaphragm ) birth control pill 8 . The patient history know allergy suspicion allergy NOVOCART® Disc plus oder basic product component include hyaluronan , polyethylenglycol albumin 9 . Immune defect affinity infection know unknown cause 10 . The patient active systemic local microbial infection , eczematization inflammable skin alteration site surgery ( include Protozoonosis : Babesiosis , Trypanosomiasis ( e.g . ChagasDisease ) , Leishmaniasis , persistent bacterial infection , like Brucellosis , spot typhus fever , Rickettsiosis , Leprosy , Recurrent Fever , Melioidosis Tularaemia ) . 11 . The patient unable undergo magnetic resonance imaging ( MRI ) 12 . The patient history suspicion disease chronically inflammable character , rheumatoid arthritis , gout , pseudogout , metabolic bone disease , Crohn 's disease , ulcerative colitis , lupus erythematosus , autoimmune disorder 13 . Known osteoporosis 14 . The patient primary hyperparathyroidism hyperthyroidism , chronic renal failure previous fragility fracture . 15 . Systemic connective tissue collagen disease 16 . Hereditary ocular degeneration unclear diagnosis , retinopathy base connective tissuedefined cause , macular corneal dystrophy , ( base fact human cornea express cartilage specific proteins essential functional element thus may serve indicator parallel degenerative event various cartilaginous tissue ) 17 . The patient immune suppression 18 . The patient history blood coagulation disease different genesis , include know haemorrhagic diathesis unknown cause 19 . The patient undergone chemo radiotherapy within past 5 year , cancer nonmelanoma skin cancer treat curative intent within past 5 year 20 . Known diabetes , drug treat 21 . Ulterior concomitant diseases functional impairment specific organ , exclude study participation assessment investigator 22 . The patient prisoner Radiological Exclusion Criteria • 1 . The patient apparent degenerative change lumbar spine determine Modic Changes 23 2 . The patient one dysplastic vertebral body within lumbar spine 3 . The patient sacralised lumbar vertebra LWK5 level treat NOVOCART® Disc plus oder NOVOCART® Disc basic 4 . The patient previous acute spondylodiscitis 5 . Segmental instability ( spondylolisthesis &gt; 5 mm ) translation &gt; 3 mm 6 . The patient isthmic spondylolisthesis , ankylose spondylitis spondylolysis 7 . The patient lumbar scoliosis ( &gt; 11° deformation ) . 8 . The patient previous trauma , discography surgical intervention lumbar spine . 9 . The patient previous compression burst fracture level ( ) treat NOVOCART® Disc plus NOVOCART® Disc basic 10 . The patient central spinal canal stenosis evidence narrow &lt; 8 mm ( MRI , sagittal ) 11 . The patient spinal tumor 12 . The patient metabolic bone disease 13 . The patient facet ankylosis severe facet degeneration . 14 . The patient lumbar kyphosis Intrasurgery ( tissue explant/sequestrectomy ) Exclusion Criteria 1 . Extensive damage Anulus , subsequently pose significantly great risk recurrence . Exclusion criterion determine tissue explant/sequestrectomy 1 . HIV infection 2 . Treponema pallidum ( syphilis ) infection 3. active hepatitis B C infection Exclusion Criteria prior Transplantation/Implantation 1 . Recurrent disc herniation surgery prior transplantation/implantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>degenerative disc</keyword>
	<keyword>herniated disc</keyword>
	<keyword>sequestrectomy</keyword>
	<keyword>Autologous Disc Chondrocyte Transplantation</keyword>
	<keyword>nucleotomy</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>treatment</keyword>
	<keyword>lumbar spine</keyword>
	<keyword>low back pain</keyword>
	<keyword>adjacent degenerative disc</keyword>
	<keyword>black disc</keyword>
	<keyword>NOVOCART</keyword>
</DOC>